Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Operating Leases (2019 - 2025)

Historic Operating Leases for Neurocrine Biosciences (NBIX) over the last 6 years, with Q4 2025 value amounting to $471.3 million.

  • Neurocrine Biosciences' Operating Leases rose 355.97% to $471.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $471.3 million, marking a year-over-year increase of 355.97%. This contributed to the annual value of $471.3 million for FY2025, which is 355.97% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Operating Leases stood at $471.3 million, which was up 355.97% from $479.7 million recorded in Q3 2025.
  • Neurocrine Biosciences' Operating Leases' 5-year high stood at $493.1 million during Q1 2025, with a 5-year trough of $103.7 million in Q3 2023.
  • Its 4-year average for Operating Leases is $279.8 million, with a median of $286.2 million in 2024.
  • In the last 5 years, Neurocrine Biosciences' Operating Leases skyrocketed by 17598.84% in 2024 and then skyrocketed by 355.97% in 2025.
  • Neurocrine Biosciences' Operating Leases (Quarter) stood at $121.9 million in 2021, then surged by 111.89% to $258.3 million in 2023, then soared by 76.19% to $455.1 million in 2024, then increased by 3.56% to $471.3 million in 2025.
  • Its last three reported values are $471.3 million in Q4 2025, $479.7 million for Q3 2025, and $489.8 million during Q2 2025.